Since the physiological impairment of PAH includes in-situ thrombosis1, 2, the alteration of the down-regulated CFHR2 in PAH patients may reflect the pathological changes of the coagulant system in PAH patients and the plasma level of this factor is also possibly developed as a biomarker of PAH. This evidence concerns the gene CFHR2 and pulmonary arterial hypertension.